Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
2 julho 2026
Herbert Smith Freehills Kramer advises Transpower on New Zealand undersea cable supply link upgrade
Leading global law firm Herbert Smith Freehills Kramer (HSF Kramer) has advised New Zealand’s national grid owner and system operator, Transpower, on an …
2 julho 2026
Herbert Smith Freehills Kramer advises Pengana Capital Group on the IPO of its AI Private Opportunities Trust
HSF Kramer has advised Australian fund manager Pengana Capital Group on the $267m initial public offering (IPO) and ASX Listing of the AI Private …
2 julho 2026
Herbert Smith Freehills Kramer advises MASECO on its acquisition by Creative Planning
Herbert Smith Freehills Kramer has advised MASECO LLP, a London-based registered investment adviser ("RIA") specialising in cross-border wealth …